Goldman Sachs Maintains Buy on Abbott Laboratories, Raises Price Target to $154
ABTMarch 4, 2025
Read more →Cadrenal Therapeutics Announces Collaboration Agreement With Abbott In Support Of Pivotal Study Of Tecarfarin In Patients With HeartMate 3 LVAD
ABTMarch 4, 2025
Read more →What Does the Market Think About Abbott Laboratories?
ABTFebruary 28, 2025
Read more →Analyst Cautiously Optimistic On DexCom As Competitive Pressures Loom
ABTDexCom reported Q4 revenue of $1.11 billion, surpassing estimates. The company reaffirmed its 2025 outlook while analysts highlighted long-term growth potential.
February 14, 2025
Read more →Rep. Emily Randall Has Sold Up to $165K Worth Of Abbott Laboratories Stock: Here's What You Should Know
ABTFebruary 12, 2025
Read more →FDA Bans Red Dye No. 3 Effective January 2027, Cites Cancer Risks: Food Stocks To Watch
ABTThe U.S. Food and Drug Administration announced a ban on Red No. 3, an artificial food coloring linked to cancer in animal studies, effective Jan. 15, 2027.
January 15, 2025
Read more →Abbott And DexCom Settle Global Patent Disputes Over Continuous Glucose Monitoring Products; Agreement Dismisses All Cases And Includes 10-Year Non-Litigation Provision With No Financial Payments
ABTDecember 23, 2024
Read more →Insulet Announces Omnipod 5 System Is Now Compatible With Abbott's FreeStyle Libre 2 Plus Sensor In The U.S.
ABTNovember 20, 2024
Read more →Abbott's Amplatzer Amulet Device Demonstrates Superior Long-Term Stroke Prevention And Reduced Blood-Thinner Use In AFib Patients Compared To Watchman; Five-Year Data Presented At AHA 2024 And Published In JACC
ABTNovember 18, 2024
Read more →Plant-Based API Market Poised To Hit $52 Billion By 2034, Driven By Psychedelics And Cannabinoids
ABTNovember 16, 2024
Read more →Analyst Ratings For Abbott Laboratories
ABTNovember 5, 2024
Read more →Barclays Maintains Overweight on Abbott Laboratories, Raises Price Target to $149
ABTNovember 5, 2024
Read more →Abbott's Esprit BTK System Shows Sustained Two-Year Benefits For Treating Severe Peripheral Artery Disease Below The Knee
ABTNovember 4, 2024
Read more →Reported October 31: Abbott Laboratories And Reckitt Benckiser Win First Trial In Premature-Infant Formula Litigation, Cleared Of Allegations Of Hiding Bowel Disease Risks
ABTNovember 1, 2024
Read more →Critical Insights From Abbott Laboratories Analyst Ratings: What You Need To Know
ABTMay 22, 2024
Read more →Citigroup Maintains Buy on Abbott Laboratories, Lowers Price Target to $119
ABTMay 22, 2024
Read more →Jim Cramer Calls This Healthcare Stock A 'Worthy Spec,' Recommends Avoiding Canada Goose
ABTCramer recommends staying away from Canada Goose, even though it reported better-than-expected Q4 earnings.
May 21, 2024
Read more →FDA Warns of Clip Lock Malfunctions With Abbott's MitraClip Heart Valve Devices
ABTThe FDA alerted healthcare providers about the potential for clip lock malfunctions with Abbott Laboratories (NYSE: ABT) MitraClip's delivery system to stop heart valve leakage.
September 9, 2022
Read more →FDA Warns Of Potential Clip Lock Issue With Abbott's Heart Valve Repair Device
ABTSeptember 8, 2022
Read more →Abbott Reports FDA Clearance For Its Test To Simultaneously Detect 4 Common Sexually-Transmitted Infections
ABTMay 4, 2022
Read more →Here's How Much $100 Invested In Abbott Laboratories 5 Years Ago Would Be Worth Today
ABTAbbott Laboratories (NYSE:ABT) has outperformed the market over the past 5 years by 8.78% on an annualized basis producing an average annual return of 20.13%. Currently, Abbott Laboratories has a market capitalization of $196.98 billion.
May 2, 2022
Read more →Peering Into Abbott Laboratories's Recent Short Interest
ABTAbbott Laboratories's (NYSE:ABT) short percent of float has fallen 9.21% since its last report. The company recently reported that it has 12.10 million shares sold short, which is 0.69% of all regular shares that are available for trading.
May 2, 2022
Read more →